Serious adverse events · healthy individuals and those with a pre‐existing health condition
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · participants with depressive or anxiety disorders
It is very uncertain whether discontinuation by "tapering" changes relapse (as defined by study authors) (HR) compared with continuation (or usual care) (very low certainty).
1 finding from 1 review
Withdrawal symptoms · participants with depressive or anxiety disorders
1 finding from 1 review
Adverse events · participants with depressive or anxiety disorders
It is very uncertain whether discontinuation by "tapering" changes adverse events compared with continuation (or usual care) (very low certainty).
1 finding from 1 review
Depressive symptoms · participants with depressive or anxiety disorders
1 finding from 1 review
Anxiety · participants with depressive or anxiety disorders
1 finding from 1 review
Quality of life · participants with depressive or anxiety disorders
1 finding from 1 review
Social and occupational functioning · participants with depressive or anxiety disorders
1 finding from 1 review
Successful discontinuation rate · participants with depressive or anxiety disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe hypoglycaemia
Summary of findings: insulin glargine showed no clear difference in severe hypoglycaemia (n/N) Definition: symptomatic hypoglycaemia… compared with NPH insulin (moderate certainty).
1 finding from 1 review
Non‐fatal myocardial infarction/stroke Definition: myocardial infarction/cerebral ischaemia
1 finding from 1 review
Severe nocturnal hypoglycaemia (n/N) Definition: severe hypoglycaemia occurring 00:01‐05:59 (Davies 2014) or 23:00‐07:00 (BEGIN Young)
Summary of findings: insulin glargine showed no clear difference in severe nocturnal hypoglycaemia (n/N) Definition: severe… compared with NPH insulin (moderate certainty).
1 finding from 1 review
Serious adverse events (n/N)
Summary of findings: insulin glargine showed no clear difference in serious adverse events (n/N) compared with NPH insulin (moderate certainty).
1 finding from 1 review
All‐cause mortality
1 finding from 1 review
Health‐related quality of life
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe hypoglycaemia
It is very uncertain whether summary of findings: insulin detemir changes severe hypoglycaemia (n/N) Definition: hypoglycaemia requiring third… compared with insulin glargine (very low certainty).
1 finding from 1 review
Non‐fatal myocardial infarction/stroke
1 finding from 1 review
Severe nocturnal hypoglycaemia (n/N) Definition: severe hypoglycaemia occurring 00:01‐05:59 (Davies 2014) or 23:00‐07:00 (BEGIN Young)
It is very uncertain whether summary of findings: insulin detemir changes severe nocturnal hypoglycaemia (n/N) Definition: severe… compared with insulin glargine (very low certainty).
1 finding from 1 review
Serious adverse events (n/N)
Summary of findings: insulin detemir showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).
1 finding from 1 review
HbA1c (%)
1 finding from 1 review